Sight Sciences Q1 revenue up 26% to $18.8M, net loss $17.1M; reaffirms FY2023 guidance

Sight Sciences, Inc.

2023-Q1 EPS reported -$0.35 revenue$18,824,000

Revenue $18.8M (+26% YoY); Surgical Glaucoma $17.3M (+25%), Dry Eye $1.5M (+47%).
Net loss $17.1M ($0.35/share) vs $23.3M ($0.49) prior year; operating expenses decreased 2% to $33.3M.
Gross margin improved to 84% from 80% due to prior year voluntary TearCare SmartHub replacement.
Reaffirmed FY2023 revenue guidance $89-94M (25-32% growth) and ~$30.5M quarterly adjusted opex.
Completed commercial launch of Ergo-Series OMNI Surgical System; cash $167.3M, debt $35.0M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sight Sciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $18.8 million, net income $17.1 million, EPS ($0.35) per share. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $18.8 million
Net income: $17.1 million
EPS: ($0.35) per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

results for the first quarter ended March 31, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights • Generated first quarter revenue of $18.8 million, an increase of 26% compared to the prior year period • Achieved gross margin of 84% in the first quarter of 2023 versus 80% in the first quarter of 2022 • Completed the

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sight Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-017868

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.